|Registry of biomedical companies:
   [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 556 active entries
102, avenue Gaston Roussel
Phone: +33 1 41 83 99 00
Fax: +33 1 41 83 99 03
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
Cellectis S.A. is a world leader in genome engineering and genome surgery. The company focuses on developing and producing custom meganucleases for use in vivo genome surgery in the therapeutic, agrifood, biomanufacturing and research sectors. Meganucleases are a particular class of endonucleases, proteins that bind and cut DNA at specific target sites. Cellectis has developed a high-throughput screening platform to generate customized meganucleases, in order to site-direct recombination at natural loci in any living cells.
Cellectis is a spin off from Institut Pasteur and capitalizes on 15 years of research on homologous recombination, Meganucleases and their combined uses in mammalian cells. It was founded in late 1999, and is based in the Aventis Biocitech Technology Park in Romainville, Paris area.
Worldwide, Cellectis has entered into more than 50 agreements with major players in the pharma, biotech and agribiotech industries and has over 20 collaborations with academic research groups. To date, Cellectis has raised over €50 million in both equity operations and public financing and is listed on the NYSE-Euronext Alternext market (ticker code: ALCLS).
Last update of this entry: October 06, 2009